The Experts below are selected from a list of 2010 Experts worldwide ranked by ideXlab platform

Goran Wallin - One of the best experts on this subject based on the ideXlab platform.

  • anaplastic Giant Cell Carcinoma of the thyroid gland treatment and survival over a 25 year period
    World Journal of Surgery, 1998
    Co-Authors: Ola Nilsson, Johan Lindeberg, Jan Zedenius, Eva Tallroth Ekman, Jan Tennvall, H Blomgren, Lars Grimelius, Goran Lundell, Goran Wallin
    Abstract:

    Anaplastic Giant Cell Carcinoma of the thyroid gland: treatment and survival over a 25-year period.

  • anaplastic Giant Cell Carcinoma of the thyroid gland treatment and survival over a 25 year period
    World Journal of Surgery, 1998
    Co-Authors: Ola Nilsson, Johan Lindeberg, Jan Zedenius, Eva Tallroth Ekman, Jan Tennvall, H Blomgren, Lars Grimelius, Goran Lundell, Goran Wallin
    Abstract:

    Anaplastic Giant Cell Carcinoma of the thyroid is a rare but highly malignant tumor. At the Karolinska Hospital in Stockholm, surgery, chemotherapy, and radiotherapy have been used separately or in various combinations in 81 patients admitted with this diagnosis during 1971-1997. In this study, we present the various multimodality treatment regimens and their changes over the years and the subsequent differences in survival and local tumor control. Overall, eight patients (10%) survived more than 2 years. All survivors were treated with combinations of chemotherapy, radiotherapy, and surgery. Among the patients who died, local tumor control was achieved by the therapy given in many cases. The results suggest that our current strategy with a combination of preoperative hyperfractionated accelerated radiotherapy, doxorubicin pre- and postoperatively, and debulking surgery whenever possible results in better local tumor control and an increased chance of survival.

Lisa J Whiteley - One of the best experts on this subject based on the ideXlab platform.

  • gene fusion characterisation of rare aggressive prostate cancer variants adenosquamous Carcinoma pleomorphic Giant Cell Carcinoma and sarcomatoid Carcinoma an analysis of 19 cases
    Histopathology, 2020
    Co-Authors: Mohamed Alhamar, Liang Cheng, Tudor I Vladislav, Steven C Smith, Yuan Gao, Laura Favazza, Ali M Alani, Michael Ittmann, Nicole D Riddle, Lisa J Whiteley
    Abstract:

    Aims To evaluate the molecular underpinnings of the rare aggressive prostate cancer variants adenosquamous Carcinoma, pleomorphic Giant-Cell Carcinoma, and sarcomatoid Carcinoma. Methods and results We retrieved 19 tumours with one or more variant(s), and performed ERG immunohistochemistry, a next-generation sequencing assay targeting recurrent gene fusions, and fluorescence in-situ hybridisation (FISH) for ERG and BRAF. Divergent differentiation included: sarcomatoid Carcinoma (n = 10), adenosquamous Carcinoma (n = 7), and pleomorphic Giant-Cell Carcinoma (n = 7). Five patients had more than one variant. Four had variants only in metastases. ERG rearrangement was detected in nine (47%, seven via sequencing, showing TMPRSS2-ERG fusions and one GRHL2-ERG fusion, and two via FISH, showing rearrangement via deletion). ERG was immunohistochemically positive in the adenoCarcinoma in eight of nine (89%) patients, but was immunohistochemically positive in the variant in only five of nine patients (56%, typically decreased). One patient had a false-positive ERG immunohistochemical result in the sarcomatoid component despite a negative FISH result. Two (11%) harboured BRAF fusions (FAM131A-BRAF and SND1-BRAF). Conclusions ERG fusions are present in these rare prostate cancer variants with a frequency close to that in conventional prostate cancer (9/19, 47%). ERG immunohistochemistry usually detects rearrangement in the adenoCarcinoma, but is less sensitive for the variant histology, with weak to negative staining. Adenosquamous and sarcomatoid variants can, particularly, occur together. Molecular assessment may be an additional tool in selected cases to confirm the prostatic origin of unusual tumours. The presence of two BRAF rearrangements suggests that this gene fusion may be enriched in this setting, as RAF kinase fusions have been previously reported in 1-2% of prostate cancers.

Ola Nilsson - One of the best experts on this subject based on the ideXlab platform.

  • anaplastic Giant Cell Carcinoma of the thyroid gland treatment and survival over a 25 year period
    World Journal of Surgery, 1998
    Co-Authors: Ola Nilsson, Johan Lindeberg, Jan Zedenius, Eva Tallroth Ekman, Jan Tennvall, H Blomgren, Lars Grimelius, Goran Lundell, Goran Wallin
    Abstract:

    Anaplastic Giant Cell Carcinoma of the thyroid gland: treatment and survival over a 25-year period.

  • anaplastic Giant Cell Carcinoma of the thyroid gland treatment and survival over a 25 year period
    World Journal of Surgery, 1998
    Co-Authors: Ola Nilsson, Johan Lindeberg, Jan Zedenius, Eva Tallroth Ekman, Jan Tennvall, H Blomgren, Lars Grimelius, Goran Lundell, Goran Wallin
    Abstract:

    Anaplastic Giant Cell Carcinoma of the thyroid is a rare but highly malignant tumor. At the Karolinska Hospital in Stockholm, surgery, chemotherapy, and radiotherapy have been used separately or in various combinations in 81 patients admitted with this diagnosis during 1971-1997. In this study, we present the various multimodality treatment regimens and their changes over the years and the subsequent differences in survival and local tumor control. Overall, eight patients (10%) survived more than 2 years. All survivors were treated with combinations of chemotherapy, radiotherapy, and surgery. Among the patients who died, local tumor control was achieved by the therapy given in many cases. The results suggest that our current strategy with a combination of preoperative hyperfractionated accelerated radiotherapy, doxorubicin pre- and postoperatively, and debulking surgery whenever possible results in better local tumor control and an increased chance of survival.

Jan Zedenius - One of the best experts on this subject based on the ideXlab platform.

  • Papillary thyroid Carcinoma with pleomorphic tumor Giant Cells in a pregnant woman – a case report
    'Springer Science and Business Media LLC', 2018
    Co-Authors: Johan O. Paulsson, Jan Zedenius, Christofer C. Juhlin
    Abstract:

    Abstract Background Papillary thyroid Carcinoma with pleomorphic tumor Giant Cells (PTC-PC) is characterized by the occurrence of bizarre, pleomorphic Cells within a small area of a conventional PTC. The histologic distinction between PTC-PC and PTC’s with a focal anaplastic thyroid cancer (ATC) component (denoted in the 2004 WHO classification as “papillary thyroid Carcinoma with spindle and Giant Cell Carcinoma”, PTC-SGC) is debated, however the prognosis is thought to be different (exCellent for PTC-PC, poor for PTC-SGC). Therefore, this diagnostic challenge is significant for any endocrine pathologist to recognize. Herein, we report the histological and clinical workup of a PTC-PC case, with particular focus on the molecular analyses that facilitated the establishment of the final diagnosis. Case presentation The patient was a pregnant, 28-year-old female presenting with a 30 mm conventional PTC, with focal areas with undifferentiated Cells exhibiting exaggerated nuclear pleomorphism. No foci of extrathyroidal extension, angioinvasion or lymph node engagement were seen. Immunohistochemical analyses revealed the pleomorphic Cells exhibiting retained differentiation. Molecular genetic analyses demonstrated a codon V600 missense mutation of the BRAF gene, but no TP53 or TERT promoter mutations. The absence of an aggressive phenotype in addition to the lack of mutations in two major ATC-related genes led to the diagnosis of a PTC-PC. Postoperative MRI showed no evidence of metastatic disease. Radioiodine ablation was performed seven months post-operatively, and a SPECT-CT imaging did not show signs of residual tissue. She is well and without signs of disease 16 months post-operatively. Conclusions PTC-PC is a differential diagnosis to PTC-SGC that mandates careful considerations. Taken together with previous publications, PTC-PC seems to be histologically similar to PTC-SGC, but clinically distinct. Even so, the distinction is not easily made given the different therapeutic consequences for each individual patient. This is the first report that includes molecular genetics to aid in finalizing the diagnosis. Exclusion of mutations in TP53 and the TERT promoter could be considered as an adjunct tool when assessing papillary thyroid cancer with focal pleomorphism

  • anaplastic Giant Cell Carcinoma of the thyroid gland treatment and survival over a 25 year period
    World Journal of Surgery, 1998
    Co-Authors: Ola Nilsson, Johan Lindeberg, Jan Zedenius, Eva Tallroth Ekman, Jan Tennvall, H Blomgren, Lars Grimelius, Goran Lundell, Goran Wallin
    Abstract:

    Anaplastic Giant Cell Carcinoma of the thyroid gland: treatment and survival over a 25-year period.

  • anaplastic Giant Cell Carcinoma of the thyroid gland treatment and survival over a 25 year period
    World Journal of Surgery, 1998
    Co-Authors: Ola Nilsson, Johan Lindeberg, Jan Zedenius, Eva Tallroth Ekman, Jan Tennvall, H Blomgren, Lars Grimelius, Goran Lundell, Goran Wallin
    Abstract:

    Anaplastic Giant Cell Carcinoma of the thyroid is a rare but highly malignant tumor. At the Karolinska Hospital in Stockholm, surgery, chemotherapy, and radiotherapy have been used separately or in various combinations in 81 patients admitted with this diagnosis during 1971-1997. In this study, we present the various multimodality treatment regimens and their changes over the years and the subsequent differences in survival and local tumor control. Overall, eight patients (10%) survived more than 2 years. All survivors were treated with combinations of chemotherapy, radiotherapy, and surgery. Among the patients who died, local tumor control was achieved by the therapy given in many cases. The results suggest that our current strategy with a combination of preoperative hyperfractionated accelerated radiotherapy, doxorubicin pre- and postoperatively, and debulking surgery whenever possible results in better local tumor control and an increased chance of survival.

Jan Tennvall - One of the best experts on this subject based on the ideXlab platform.

  • anaplastic Giant Cell Carcinoma of the thyroid gland treatment and survival over a 25 year period
    World Journal of Surgery, 1998
    Co-Authors: Ola Nilsson, Johan Lindeberg, Jan Zedenius, Eva Tallroth Ekman, Jan Tennvall, H Blomgren, Lars Grimelius, Goran Lundell, Goran Wallin
    Abstract:

    Anaplastic Giant Cell Carcinoma of the thyroid gland: treatment and survival over a 25-year period.

  • anaplastic Giant Cell Carcinoma of the thyroid gland treatment and survival over a 25 year period
    World Journal of Surgery, 1998
    Co-Authors: Ola Nilsson, Johan Lindeberg, Jan Zedenius, Eva Tallroth Ekman, Jan Tennvall, H Blomgren, Lars Grimelius, Goran Lundell, Goran Wallin
    Abstract:

    Anaplastic Giant Cell Carcinoma of the thyroid is a rare but highly malignant tumor. At the Karolinska Hospital in Stockholm, surgery, chemotherapy, and radiotherapy have been used separately or in various combinations in 81 patients admitted with this diagnosis during 1971-1997. In this study, we present the various multimodality treatment regimens and their changes over the years and the subsequent differences in survival and local tumor control. Overall, eight patients (10%) survived more than 2 years. All survivors were treated with combinations of chemotherapy, radiotherapy, and surgery. Among the patients who died, local tumor control was achieved by the therapy given in many cases. The results suggest that our current strategy with a combination of preoperative hyperfractionated accelerated radiotherapy, doxorubicin pre- and postoperatively, and debulking surgery whenever possible results in better local tumor control and an increased chance of survival.